From before the coronavirus disease 2019 (COVID-19) pandemic, the effect of dipeptidyl peptidase 4 inhibitors (DPP-4i) on respiratory infections (RI) remains unclear. The meta-analysis of Yang et al. (1) specifically assessed the risk of infection with DPP-4i. However, cardiovascular outcomes
Reviewed by Nieca Goldberg, M.D.In 1994, iconic singer Patti LaBelle lived every performer’s worst nightmare — she collapsed on stage in front of thousands of fans. LaBelle attributed her fall to exhaustion until she learned she had Type 2 diabetes.
Impact of Obesity on Measures of Cardiovascular and Kidney Health in Youth With Type 1 Diabetes as Compared With Youth With Type 2 Diabetes Kalie L. Tommerdahl, Karl Baumgartner, Michal Schäfer, Petter Bjornstad, Isabella Melena, Shannon Hegemann, Amy D. Baumgartner,
IntroductionEvolving treatment recommendations in type 2 diabetes are being driven by randomized controlled trials (RCTs), which have become the gold standard of clinical evidence and the staple of guided clinical practice. Reports of RCTs now crowd the pages of both
Meta-analyses and reviews of observational cohorts have reported a relationship between severe hypoglycemia (SH) and atherosclerotic cardiovascular disease (ASCVD) events, but estimates of effect vary widely and many studies are limited by size and diversity, ability to adjust for confounders,
Patients with type 2 diabetes are at high risk of developing renal and cardiovascular complications. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have garnered interest due to their glucose-independent cardiorenal protective effects, as reported in trials including participants with and without diabetes,
AbstractBACKGROUND Evidence suggests that vitamin C supplementation could be a potential therapy in type 2 diabetes. However, its effectiveness and evidence quality require further evaluation.PURPOSE To investigate the efficacy of oral vitamin C supplementation in improving glycemic control, cardiovascular risk
AbstractOBJECTIVE There is growing evidence linking time in range (TIR), an emerging metric for assessing glycemic control, to diabetes-related outcomes. We aimed to investigate the association between TIR and mortality in patients with type 2 diabetes.RESEARCH DESIGN AND METHODS A
Over the last two decades, the large majority of clinical guidelines on the treatment of hyperglycemia in subjects with type 2 diabetes have suggested metformin as the first-line glucose-lowering treatment alongside lifestyle changes to reach personalized glycemic targets. Recently, the
Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes Nete Tofte, Simone Theilade, Signe A. Winther, Sørine Birkelund, Jens P. Goetze, Tine W. Hansen, Peter Rossing Diabetes Care